GeneThera, Inc. Logo

GeneThera's E. Coli Vaccine Featured on CBS, Channel 4 News In Denver, Colorado

GeneThera Identifies Need for Government Action to Prevent Future E. Coli Outbreaks

| Source: GeneThera, Inc.

DENVER, SAN JOSE, Calif. and BOISE, Idaho, Feb. 10, 2009 (GLOBE NEWSWIRE) -- GeneThera, Inc. (Pink Sheets:GTHR), a leading international biotechnology company dedicated to improving food safety, was recently interviewed on Denver CBS Affiliate Channel 4, KCNC-TV. The interview was conducted as a result of an E. Coli outbreak linked to the National Western Stock Show.

The 3-1/2 minute interview took place at GeneThera's research and development laboratory in Wheat Ridge, Colorado. Click here to view the video coverage:

"GeneThera tests cattle and conducts research on E. Coli, Mad Cow Disease, and Johne's Disease. In addition to this we have a vaccine for E. Coli, which can be administered to calves. Through these efforts we can effectively eliminate 99% of E.Coli outbreaks," noted Dr. Tony Milici, President of GeneThera. "We are already getting involved with the Mexican Government and have received some interest from the Canadian Government."

In 2008 there were multiple E. Coli outbreaks across the United States. The largest recall affected seven states and sickened 49 people. This outbreak alone caused the recall of 5.3 Million pounds of beef.


The largest single outbreak was in Oklahoma, and eventually sickened nearly 200 people.


"It would have been cheaper for the cattle farmers and meat processors to test and vaccinate their cattle than to suffer through a recall, and have to compensate the sickened and their families." continued Dr. Milici. Currently the U.S. Beef Industry spends $350 Million every year in food safety.

A list of USDA recalls can be found here:

GeneThera has received numerous calls from other local and regional news outlets for interviews and follow up on E.Coli and the peanut butter salmonella contamination. The company has also received calls from cattle ranchers who are seeking to buy the company's products. GeneThera has received distribution inquiries from major biotech and/or veterinary distribution companies and is currently evaluating its options.

"Last week Michael Homer, co-founder of Netscape, died due to a form of Mad Cow Disease. We are working to identify which cattle are infected with BSE. We also have a vaccine to stop E.Coli. All we need to ensure public safety is government action or incentives for ranchers. With a little government support our solutions could help prevent future outbreaks and deaths."

Tests will cost $15-20 retail and E. Coli vaccination will be approximately $15-$25 per head of cattle. The U.S. market (not including Canada, Mexico, and abroad) would be nearly 220 million cattle and dairy cows.


GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For more information, contact Dr. Tony Milici at 303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370.

The GeneThera, Inc. logo is available at

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

GeneThera, Inc.
Dr. Tony Milici 

Goldsmith Group 

JR Dopkin & Associates